INmune Bio (NASDAQ:INMB) Price Target Raised to $23.00

INmune Bio (NASDAQ:INMB) had its price target upped by Scotiabank from $22.00 to $23.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a sector outperform rating on the stock.

INMB has been the subject of a number of other research reports. Alliance Global Partners assumed coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price for the company. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on INmune Bio in a report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $22.80.

INmune Bio Trading Up 1.9 %

NASDAQ INMB opened at $9.30 on Tuesday. INmune Bio has a 1-year low of $4.32 and a 1-year high of $14.74. The stock has a 50-day moving average of $6.44 and a 200-day moving average of $6.11. The firm has a market cap of $206.18 million, a PE ratio of -4.27 and a beta of 1.87.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN grew its holdings in shares of INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after acquiring an additional 2,155 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock worth $53,000 after acquiring an additional 5,461 shares during the period. Mariner LLC purchased a new position in shares of INmune Bio during the 4th quarter worth approximately $65,000. Financial Advocates Investment Management grew its holdings in shares of INmune Bio by 14.8% during the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after acquiring an additional 2,000 shares during the period. Finally, Rhumbline Advisers grew its holdings in shares of INmune Bio by 16.9% during the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock worth $78,000 after acquiring an additional 2,424 shares during the period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.